Companies: 10,795·Total market cap: $144.5T
Helix BioPharma Corp.

Helix BioPharma Corp.

HBP.TOTSXHealthcare● Active
$1.53
$-0.05(-3.16%)
Market Cap$116858490
P/E Ratio—
52W High$5.4
52W Low$0.84
Cash on HandFinancialsRevenue

Helix BioPharma Corp. (HBP.TO) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

HBP.TO · cash on hand · updated Jul 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$65,000▼ -94.0% vs prior year
FY · as of Jul 31, 2025 · Reported in CAD
Cash & Cash Equiv. (CCE)
$65,000
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
-94.0%
vs prior fiscal year
Latest Quarter
$31,000
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in CAD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: July 31, 2025

Net cash vs debt

Cash & ST Investments$65,000Cash on Hand
Total Debt$335,000Total Debt
Net Cash / Net Debt−$270,000Net Debt Position
Cash vs Debt Ratio
Cash 16%Debt 84%

Helix BioPharma Corp. carries a net debt position of $270,000. Total debt ($335,000) exceeds cash on hand ($65,000). Helix BioPharma Corp. cash vs debt ratio: 16% cash / 84% debt.

Net Cash = Cash & ST Investments − Total Debt$65,000 − $335,000 = −$270,000

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
HBP.TO annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Jul 31, 2025Latest$0.1M-94.0%
Jul 31, 2024$1.1M+33.8%
Jul 31, 2023$0.8M-75.2%
Jul 31, 2022$3.3M-8.8%
Jul 31, 2021$3.6M-15.8%
HBP.TO cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Helix BioPharma Corp.
Helix BioPharma Corp.YOU
HBP.TO
$0.1M0.1%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Helix BioPharma Corp. (HBP.TO) cash on hand as of July 31, 2025 is $65,000, comprising $65,000 in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Helix BioPharma Corp. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Helix BioPharma Corp. cash reserves or cash position.

Helix BioPharma Corp. annual cash on hand history shows decreased -94.0% in 2025: decreased -94.0% in 2025. Helix BioPharma Corp. cash reserves in 2025 reflect the company's capital allocation strategy.

Helix BioPharma Corp. carries total debt of $335,000 against cash of $65,000, resulting in a net debt position of -$270,000. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

HBP.TO cash on hand · 5 questions

As of July 31, 2025, Helix BioPharma Corp. (HBP.TO) has $65,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $65,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (January 31, 2026): $31,000. Data sourced from the annual 10-K filing via FMP.

HBP.TO cash on handHBP.TO cash reservesHBP.TO cash 2025how much cash does HBP.TO have

▸ Source: FMP /balance-sheet-statement · US GAAP · Helix BioPharma Corp. · Helix BioPharma Corp. SEC 10-K & 10-Q filings · US GAAP · Last updated: July 31, 2025